Low Financial Leverage (no Debt)Zero reported debt reduces bankruptcy and interest-rate risk for a development-stage biotech. Over 2–6 months this preserves financial optionality and lowers fixed-cost burdens, giving management flexibility to time financing or advance clinical programs without debt servicing constraints.

Focused Drug Program In Large MarketsA concentrated R&D focus on TRPV1 antagonist XEN-D0501 targets structurally large, chronic markets (type 2 diabetes, obesity). This strategic clarity concentrates resources on a single value-driving asset, aligning long-term upside to favourable secular demand in metabolic disease if clinical progress continues.

Reduced Peak Losses Vs 2022Earnings show smaller losses since the 2022 peak, indicating some improvement in cost control or program pacing. Over several months this suggests management can moderate burn or reallocate spend, which can extend runway and reduce near-term financing frequency if the trend persists.

Bears Say

Accelerating Cash BurnWorsening free cash flow reflects accelerating cash consumption, which materially increases reliance on external financing for operations and trials. Over a 2–6 month horizon this heightens dilution risk and constrains the company’s ability to independently fund development milestones or expand programs.

Declining, Volatile RevenueSmall and falling revenue undermines capacity to fund R&D or transition to commercialization. Structurally, lack of consistent top-line performance reduces operating leverage and increases dependency on capital markets or partners to finance development, a persistent weakness for sustainability.

Contracted Equity CushionA sharp drop in equity reduces the balance-sheet buffer against future losses and shocks, limiting financial flexibility. This structurally raises the probability of dilutive capital raises and weakens negotiating position with partners or lenders during the next financing cycle.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.41 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is €4.89M.

When is PILA PHARMA AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PILA PHARMA AB’s earnings last quarter?

Currently, no data Available

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 42,084,415 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in DE:5KC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.